U.S. ITC reviews some objections of Daewoong Pharmaceutical

[Infostock Daily=Reporter Park Jeong-Do] The U.S. International Trade Commission (ITC) will review Daewoong Pharmaceutical's objection to the preliminary ruling of Daewoong Pharmaceutical and Meditox's botulinum strain dispute.

Meditox announced on July 22 that Daewoong Pharmaceutical decided to review the objection to the preliminary ruling on the source of botulinum toxin strain of the two companies in July.

Previously, the ITC banned Daewoong Pharmaceutical's botulinum toxin 'Nabota' for 10 years on the basis that "Daewoong Pharmaceutical has stolen the strain and manufacturing process of Meditox" in July. Daewoong Pharmaceutical disputed the ruling.

According to Meditox, the ITC committee consists of five members. If one decides to accept an objection, it will review it. It is a normal and general procedure for the ITC committee to review the preliminary ruling.

The lawsuit began in February last year when Meditox and Allergan (now Abbvie) filed a lawsuit against Daewoong Pharmaceutical and Evolus in the U.S. ITC. Meditox claims Daewoong Pharmaceutical stole its strain. The final review results of the ITC committee will be confirmed on November 6 (US time), and will be finalized if the US president approves them two months later.

Reporter Park Jeong-Do newface0301@naver.com